SKB BIO-B (06990) surged over 4%, reaching HK$427.4 by the time of writing, with a trading volume of HK$18.32 million. The company recently entered a collaboration with Crescent to jointly develop and commercialize novel oncology treatments, including combination therapies. The partnership involves SKB BIO-B's ADC drug SKB105 (CR-003), which targets integrin β6 (ITGB6) and carries a topoisomerase inhibitor payload, as well as Crescent's PD-1xVEGF bispecific antibody CR-001 (SKB118). Both candidates are being developed for solid tumor treatment, with Phase I/II monotherapy trials expected to commence in Q1 2026.
Tianfeng Securities noted that the collaboration includes advancing monotherapy development for both candidates while jointly evaluating the combination of CR-001 and SKB105. Each party retains the right to independently explore additional combination therapies for CR-001. CR-001, a tetravalent bispecific antibody, has demonstrated strong antitumor activity in preclinical studies.
Under the agreement, SKB BIO-B will receive an upfront payment of $80 million from Crescent, with potential milestone payments totaling up to $1.25 billion. The company is also eligible for tiered royalties on SKB105's net sales, ranging from mid-single-digit to low-double-digit percentages. Additionally, SKB BIO-B may receive further payments if Crescent undergoes a change of control or enters into a sublicensing arrangement with a third party.
Comments